Immune Thrombocytopenia clinical trials at UC Davis
1 research study open to eligible people
Showing trials for
Study to Evaluate the Effectiveness and Safety of Experimental PANZYGA in Children With Chronic Immune Thrombocytopenia (ITP)
open to eligible people ages 1-18
This is a prospective, open-label, single-arm, multicenter, Phase 4 study evaluating the efficacy and safety of PANZYGA in pediatric patients with chronic ITP.
Sacramento, California and other locations